Dr. Pomerantz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney Street
Dana-Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-4524
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007- Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
Stanford University School of MedicineClass of 2001
Certifications & Licensure
NH State Medical License 2024 - 2026
MA State Medical License 2004 - 2025
Clinical Trials
- Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer Start of enrollment: 2003 Mar 01
- International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Roles: Contact
Publications & Presentations
PubMed
- 287 citations8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYCNasim Ahmadiyeh, Mark Pomerantz, Chiara Grisanzio, Paula Herman, Li Jia
Proceedings of the National Academy of Sciences of the United States of America. 2010-05-25 - 38 citationsAtlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulationAlexander Gusev, Huwenbo Shi, Gleb Kichaev, Mark Pomerantz, Fugen Li
Nature Communications. 2016-04-07 - 179 citationsModulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancerHaiyang Guo, Musaddeque Ahmed, Fan Zhang, Cindy Q. Yao, SiDe Li
Nature Genetics. 2016-10-01
Journal Articles
- Association of Genetic Variation of the Six Gene Prognostic Model for Castration‐Resistant Prostate Cancer with SurvivalMark M Pomerantz, Philip W Kantoff, The Prostate
- A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate CancerChristopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
Press Mentions
- Incontinence and Impotence: Man Hopes to Create Discussion About Prostate CancerNovember 2nd, 2020
Prostate Cancer Metastasizes by Hijacking a Developmental Epigenetic ProgramSeptember 15th, 2020- Reddit Comic About Canadian Man's Positive Pregnancy Test Sparks Cancer DiagnosisNovember 8th, 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
